ArticleVaccines2026
Data-Driven Vaccine Clinical Trial Design Features and Associated Progress Patterns: An Analysis of 1618 Clinical Trials from 2012 to 2022.
Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND/
objectivesVaccine clinical trials face high costs, long timelines, and variable progression rates, yet systematic evidence linking trial design features to progression outcomes remains limited. This study aimed to identify trial design features associated with vaccine trial progression and to explore robust design configurations using machine learning approaches.
methodsWe analyzed 1618 vaccine trials registered from 2012 to 2022. Progression was defined as phase advancement (phase I/II) or regulatory authorization (phase III). Logistic regression assessed associations with progression. Random forest classifiers with cross-validation were used to estimate predicted progression probabilities based on combinations of design features. Monte Carlo simulations compared model-identified robust configurations with randomly generated configurations.
resultsAmong 1618 trials, 579 achieved phase progressions, corresponding to an overall observed progression rate of 35.8%. Larger sample size, preventive vaccine purpose, COVID-19 indication, and enrollment across all age groups were consistently associated with higher observed odds of progression in both univariable and multivariable logistic regression analyses. In machine learning analyses, the pooled mean predicted progression probability of model-identified robust configurations was 48.93%, compared with 39.44% for historically observed design configurations, corresponding to a relative increase of 24.1%. Simulations further showed a lower projected cumulative development duration (106.87 vs. 128.25 months; -16.7%) and reduced projected cost (USD 100.67M vs. USD 108.33M; -7.1%) for robust configurations compared with historical strategies.
conclusionsThis study provides a data-driven framework for characterizing historical vaccine trial design patterns. By integrating machine learning with observational registry data, it supports hypothesis generation and descriptive benchmarking of design features that may inform the design of future prospective or causal investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.